NeurologyB-cell Depletionmultiple sclerosis
Long-Term Ublituximab Therapy in Multiple Sclerosis: Five-Year Results from the ULTIMATE I and II Extension Study Validate Early High-Efficacy Intervention
By MedXY|Feb 20, 2026
Five-year data from the ULTIMATE I and II open-label extension demonstrate that ublituximab maintains exceptionally low relapse rates and slows disability progression in relapsing multiple sclerosis, emphasizing the clinical superiority of
